NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

Toronto, Ontario – TheNewswire - A ugust 5 , 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc ...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。